{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:48:13Z","timestamp":1787014093338,"version":"build-2736575974"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Insulin allergy is a rare yet severe side effect of exogenous insulin use. Management typically involves use of alternative antihyperglycaemic agents, symptom control with antihistamines, use of different insulin formulations, and induction of tolerance with incremental doses of insulin. This treatment regimen is not always successful, and the use of omalizumab, an anti\u2010IgE monoclonal antibody, has been used to induce tolerance to insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>\n                      G.M. is a 62\u2010year\u2010old man with Type 2 diabetes mellitus. His condition was not optimized on oral agents, and insulin therapy was required. G.M. had anaphylaxis to insulin\n                      <jats:styled-content style=\"fixed-case\">NPH<\/jats:styled-content>\n                      , and subsequent skin\u2010prick testing was positive to insulin aspart, insulin\n                      <jats:styled-content style=\"fixed-case\">NPH<\/jats:styled-content>\n                      , insulin glulisine, insulin detemir, regular insulin, insulin glargine 100 units\/ml and insulin glargine 300 units\/ml. He received incremental doses of several insulin formulations; however, he experienced diffuse urticaria preventing optimal glycaemic control. Three successful cases have been described in the literature of omalizumab inducing tolerance to exogenous insulin; therefore, G.M. was started on omalizumab. He subsequently tolerated treatment doses of insulin glulisine and insulin detemir with no allergic reactions and with improvement in glycaemic control.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our knowledge, this is the first described case of allergy to insulin glargine 300 units\/ml and reiterates the potential use of omalizumab in insulin allergy. Further research is warranted to determine if omalizumab should be considered standard of care in difficult\u2010to\u2010treat insulin hypersensitivity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dme.13591","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T13:44:09Z","timestamp":1517319849000},"page":"663-666","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Role of omalizumab in insulin hypersensitivity: a case report and review of the literature"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8694","authenticated-orcid":false,"given":"S.","family":"Mishra","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Clinical Immunology and Allergy Western University London Ontario Canada"},{"name":"Department of Medicine Dalhousie University Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Connors","sequence":"additional","affiliation":[{"name":"Department of Medicine Dalhousie University Halifax Nova Scotia Canada"},{"name":"Department of Medicine Division of General Internal Medicine (Clinical Immunology &amp; Allergy) Dalhousie University Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Department of Medicine Dalhousie University Halifax Nova Scotia Canada"},{"name":"Department of Medicine Division of Endocrinology and Metabolism Dalhousie University Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1046\/j.1398-9995.2003.00324.x","article-title":"Allergy to human insulin","volume":"58","author":"Fern\u00e1ndez L","year":"2013","journal-title":"Allergy"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01567.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.07.037"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0808282"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0115"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.10.010"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb00988.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02512.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A phase II, randomized, double\u2010blind, parallel\u2010group, placebo\u2010controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson HA","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.09.046"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.010"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.09.036"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60296-7"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.anai.2012.07.021","article-title":"Successful treatment of exercise induced anaphylaxis with omalizumab","volume":"109","author":"Bray S","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_2_7_16_1","first-page":"446","article-title":"Omalizumab: a potential new therapeutic approach for aspirin\u2010exacerbated respiratory disease","volume":"20","author":"Bobolea I","year":"2010","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2013.08.009"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-6-32"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32835bf3f5"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13591","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:01:40Z","timestamp":1695546100000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,16]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/dme.13591"],"URL":"https:\/\/doi.org\/10.1111\/dme.13591","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,16]]},"assertion":[{"value":"2018-01-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}